Last reviewed · How we verify
Diabetes mellitus — Treatment Landscape & Competitive Intelligence
7 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Tresiba | INSULIN DEGLUDEC | Novo Nordisk | Insulin Analog [EPC] | Insulin receptor | 2015-01-01 | |
| Levemir | INSULIN DETEMIR | Novo Nordisk | Insulin Analog [EPC] | Insulin receptor | 2005-01-01 | |
| Apidra | INSULIN GLULISINE | Sanofi | Insulin Analog [EPC] | Insulin receptor | 2004-01-01 | |
| Novolog | INSULIN ASPART | Novo Nordisk | Insulin Analog [EPC] | Insulin receptor | 2000-01-01 | |
| Levemir | Levemir | The Royal Bournemouth Hospital | Insulin receptor | |||
| Apidra | Apidra | Kinderkrankenhaus auf der Bult | Insulin receptor | |||
| Novolog | Novolog | Massachusetts General Hospital | Insulin receptor |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Novo Nordisk · 3 drugs in Diabetes mellitus
- Kinderkrankenhaus auf der Bult · 1 drug in Diabetes mellitus
- Massachusetts General Hospital · 1 drug in Diabetes mellitus
- Sanofi · 1 drug in Diabetes mellitus
- The Royal Bournemouth Hospital · 1 drug in Diabetes mellitus
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Diabetes mellitus:
- Diabetes mellitus treatment updates — RSS
- Diabetes mellitus treatment updates — Atom
- Diabetes mellitus treatment updates — JSON
Cite this brief
Drug Landscape (2026). Diabetes mellitus — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/diabetes-mellitus. Accessed 2026-06-10.
Related
- Diabetes mellitus full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing